Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$48.06 USD

48.06
1,012,677

-0.55 (-1.13%)

Updated Dec 5, 2024 04:00 PM ET

After-Market: $48.07 +0.01 (0.02%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.86%
3Hold9.55%
4Sell5.18%
5Strong Sell2.60%
S&P50011.25%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (64 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for HALO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 336 363 741 368 421
Receivables 234 231 91 98 59
Notes Receivable 0 0 0 0 0
Inventories 128 100 54 61 29
Other Current Assets 49 45 40 28 33
Total Current Assets 746 739 926 555 543
Net Property & Equipment 75 76 9 11 11
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 4 44 155 0 0
Intangibles 890 956 0 0 0
Deposits & Other Assets 18 27 14 15 12
Total Assets 1,733 1,842 1,104 580 566
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 12 18 2 2 6
Current Portion Long-Term Debt 0 13 89 397 20
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 101 97 24 20 56
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 3 2 2 4
Total Current Liabilities 112 131 117 421 86
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 2 3 4 1
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,499 1,493 787 0 383
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 38 46 1 3 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,649 1,672 907 429 474
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2 27 256 625 695
Retained Earnings 91 143 -59 -475 -604
Other Equity -9 -1 -1 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 84 170 197 151 92
Total Liabilities & Shareholder's Equity 1,733 1,842 1,104 580 566
Total Common Equity 84 170 197 151 92
Shares Outstanding 132.10 135.20 140.70 135.10 146.50
Book Value Per Share 0.63 1.26 1.40 1.12 0.63

Fiscal Year End for Halozyme Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents 666 529 463 336 483
Receivables 286 215 196 234 217
Notes Receivable 0 0 0 0 0
Inventories 131 159 169 128 129
Other Current Assets 44 85 46 49 49
Total Current Assets 1,127 988 874 746 879
Net Property & Equipment 74 75 78 75 75
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 1 4 13
Intangibles 836 854 872 890 907
Deposits & Other Assets 80 52 17 18 18
Total Assets 2,118 1,969 1,842 1,733 1,893
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 12 15 13 12 19
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 96 118 118 101 95
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 1
Total Current Liabilities 109 133 132 112 115
Mortgages 0 0 0 0 0
Deferred Taxes/Income 12 14 0 0 2
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,504 1,503 1,501 1,499 1,498
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 40 31 38 28
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,665 1,680 1,664 1,649 1,643
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 62 31 12 2 26
Retained Earnings 398 261 167 91 222
Other Equity -7 -2 -1 -9 1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 453 289 178 84 249
Total Liabilities & Shareholder's Equity 2,118 1,969 1,842 1,733 1,893
Total Common Equity 453 289 178 84 249
Shares Outstanding 127.20 127.20 127.00 132.10 131.90
Book Value Per Share 3.56 2.28 1.40 0.63 1.89